← Open Payments lookup

NPI 1598824351: Open Payments

NPI 1598824351. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.

See the full provider profile for registry, prescribing and billing details.

Industry payments (Sunshine Act)

Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.

$326 in 16 payments from 10 companies in 2025. Trend: 2023 $686 · 2024 $450 · 2025 $326

Food & beverage: $326
CompanyPaymentsAmount
ABBVIE INC.4$77
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)3$62
Tris Pharma Inc2$46
Neurocrine BioSciences, Inc.1$30
Almatica Pharma LLC1$24
E.R. Squibb & Sons, L.L.C.1$23
Collegium Pharmaceutical, Inc.1$19
Supernus Pharmaceuticals, Inc.1$15
Teva Pharmaceuticals USA, Inc.1$15
Corium, LLC1$13

Products named: VRAYLAR, CAPLYTA, Dyanavel XR, INGREZZA, LOREEV XR, COBENFY, Jornay PM, Qelbree.